NCT02983071View on ClinicalTrials.gov

G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

June 30, 2023

Study Completion Date

October 31, 2023

Conditions
Carcinoma, Ductal, BreastBreast CancerBreast Neoplasm
Interventions
DRUG

G1T38

DRUG

Fulvestrant

Trial Locations (8)

1330

MHAT for Womens Health - Nadezhda OOD, Sofia

1756

Special Hospital For Active Treatment In Oncology, Sofia

2025

The Institute of Oncology, Chisinau

0112

ARENSIA Exploratory Medicine LLC, Tbilisi

CB2 0QQ

Cambridge University, Cambridge

NW1 2BU

University College London Hospital (UCLH), London

W1G 6AD

Sarah Cannon Research Institute, London

M20 4BX

The Christie NHS Foundation, Manchester

Sponsors
All Listed Sponsors
lead

G1 Therapeutics, Inc.

INDUSTRY

NCT02983071 - G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter